<DOC>
	<DOCNO>NCT00915369</DOCNO>
	<brief_summary>This study multicentre , open label , non-randomized phase I study . The main objective study determine pharmacokinetic profile drug different dose level patient Advanced Breast Cancer . Maximum Tolerated Dose ( MTD ) safety Paclitaxel Nanoparticle also simultaneously assess .</brief_summary>
	<brief_title>A Clinical Trial Study Effects Nanoparticle Based Paclitaxel Drug , Which Does Not Contain Solvent Cremophor , Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Female patient histopathologically /cytologically confirm advanced breast cancer , refractory / recurrent* previous anthracycline treatment adjuvant first line therapy metastasis . Patients ER/PR ER/PR receptor status unknown ( defined histopathological evidence confirmation ER/PR status ) Patients must 1865 year age ( inclusive ) Patients ECOG performance status 0 2 Patients least one measurable lesion per RECIST Patients ER/PR positive status . Patients demonstrate HER2 expression exclude . Alternatively , patient enrol previously receive trastuzumab . HER2 expression demonstrate IHC 3+ , IHC 2+ FISH/CIS . Patients known history hypersensitivity paclitaxel taxane compound chemically / biologically relate paclitaxel excipients . Patients require concurrent chemotherapy , hormonal therapy immunotherapy , therapy biologicals radiotherapy disease . ( Patients require local radiotherapy non target bone lesion include ) . Patients know CNS lesion ( brain metastasis carcinomatous meningitis ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>